Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines

Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector–mRNA), the influence of vaccination side effects, and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerhards, Catharina, Thiaucourt, Margot, Hetjens, Michael, Haselmann, Verena, Neumaier, Michael, Kittel, Maximilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054089/
https://www.ncbi.nlm.nih.gov/pubmed/36992285
http://dx.doi.org/10.3390/vaccines11030701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054089/
https://www.ncbi.nlm.nih.gov/pubmed/36992285
http://dx.doi.org/10.3390/vaccines11030701

Ejemplares similares